1
|
Chaisupasakul P, Pekthong D, Wangteeraprasert A, Kaewkong W, Somran J, Kaewpaeng N, Parhira S, Srisawang P. Combination of ethyl acetate fraction from Calotropis gigantea stem bark and sorafenib induces apoptosis in HepG2 cells. PLoS One 2024; 19:e0300051. [PMID: 38527038 PMCID: PMC10962855 DOI: 10.1371/journal.pone.0300051] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/12/2023] [Accepted: 02/15/2024] [Indexed: 03/27/2024] Open
Abstract
The cytotoxicity of the ethyl acetate fraction of the Calotropis gigantea (L.) Dryand. (C. gigantea) stem bark extract (CGEtOAc) has been demonstrated in many types of cancers. This study examined the improved cancer therapeutic activity of sorafenib when combined with CGEtOAc in HepG2 cells. The cell viability and cell migration assays were applied in HepG2 cells treated with varying concentrations of CGEtOAc, sorafenib, and their combination. Flow cytometry was used to determine apoptosis, which corresponded with a decline in mitochondrial membrane potential and activation of DNA fragmentation. Reactive oxygen species (ROS) levels were assessed in combination with the expression of the phosphatidylinositol-3-kinase (PI3K)/ protein kinase B (Akt)/ mammalian target of rapamycin (mTOR) pathway, which was suggested for association with ROS-induced apoptosis. Combining CGEtOAc at 400 μg/mL with sorafenib at 4 μM, which were their respective half-IC50 concentrations, significantly inhibited HepG2 viability upon 24 h of exposure in comparison with the vehicle and each single treatment. Consequently, CGEtOAc when combined with sorafenib significantly diminished HepG2 migration and induced apoptosis through a mitochondrial-correlation mechanism. ROS production was speculated to be the primary mechanism of stimulating apoptosis in HepG2 cells after exposure to a combination of CGEtOAc and sorafenib, in association with PI3K/Akt/mTOR pathway suppression. Our results present valuable knowledge to support the development of anticancer regimens derived from the CGEtOAc with the chemotherapeutic agent sorafenib, both of which were administered at half-IC50, which may minimize the toxic implications of cancer treatments while improving the therapeutic effectiveness toward future medical applications.
Collapse
Affiliation(s)
- Pattaraporn Chaisupasakul
- Department of Physiology, Faculty of Medical Science, Naresuan University, Phitsanulok, Thailand
- Center of Excellence for Innovation in Chemistry, Naresuan University, Phitsanulok, Thailand
| | - Dumrongsak Pekthong
- Center of Excellence for Innovation in Chemistry, Naresuan University, Phitsanulok, Thailand
- Department of Pharmacy Practice, Faculty of Pharmaceutical Sciences, Naresuan University, Phitsanulok, Thailand
- Center of Excellence for Environmental Health and Toxicology, Faculty of Pharmaceutical Sciences, Naresuan University, Phitsanulok, Thailand
| | | | - Worasak Kaewkong
- Department of Biochemistry, Faculty of Medical Science, Naresuan University, Phitsanulok, Thailand
| | - Julintorn Somran
- Department of Pathology, Faculty of Medicine, Naresuan University, Phitsanulok, Thailand
| | - Naphat Kaewpaeng
- Center of Excellence for Innovation in Chemistry, Naresuan University, Phitsanulok, Thailand
- Department of Pharmaceutical Chemistry and Pharmacognosy, Faculty of Pharmaceutical Sciences, Naresuan University, Phitsanulok, Thailand
| | - Supawadee Parhira
- Center of Excellence for Innovation in Chemistry, Naresuan University, Phitsanulok, Thailand
- Center of Excellence for Environmental Health and Toxicology, Faculty of Pharmaceutical Sciences, Naresuan University, Phitsanulok, Thailand
- Department of Pharmaceutical Technology, Faculty of Pharmaceutical Sciences, Naresuan University, Phitsanulok, Thailand
| | - Piyarat Srisawang
- Department of Physiology, Faculty of Medical Science, Naresuan University, Phitsanulok, Thailand
- Center of Excellence for Innovation in Chemistry, Naresuan University, Phitsanulok, Thailand
- Center of Excellence in Medical Biotechnology, Faculty of Medical Science, Naresuan University, Phitsanulok, Thailand
| |
Collapse
|
2
|
Schevenels FT, Jadsadajerm S, Lekphrom R, Yodsin N, Suebrasri T, Senawong T, Wisetsai A. Siamfuranones A-C, three novel furanone derivatives from the flowers of Uvaria siamensis and their biological activities. Nat Prod Res 2024:1-10. [PMID: 38440837 DOI: 10.1080/14786419.2024.2324370] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/24/2023] [Accepted: 02/22/2024] [Indexed: 03/06/2024]
Abstract
Three previously undescribed furanone derivatives named siamfuranones A-C (1-3), together with 11 known compounds (4-14), were isolated from the flowers of Uvaria siamensis. Their planar structures were determined through analysis of spectrometric and spectroscopic evidence, while electronic circular dichroism (ECD) calculations were used to determine their absolute configurations. In addition, gauge-including atomic orbitals (GIAO) NMR chemical shift calculation, supported by the advanced statistical method DP4 plus, was used to confirm the relative configuration of siamfuranone B (2). All the isolated compounds were evaluated against two cancer cell lines (A549 and Hela), and screened for antibacterial activities. Furthermore, they were assessed for cytotoxicity against a normal cell line (Vero cell).
Collapse
Affiliation(s)
- Florian T Schevenels
- Department of Chemistry, and Center for Innovation in Chemistry, Faculty of Science, Khon Kaen University, Khon Kaen, Thailand
| | - Supachai Jadsadajerm
- Department of Industrial Chemistry, Faculty of Applied Science, King Mongkut's University of Technology North Bangkok, Bangkok, Thailand
| | - Ratsami Lekphrom
- Department of Chemistry, and Center for Innovation in Chemistry, Faculty of Science, Khon Kaen University, Khon Kaen, Thailand
| | - Nuttapon Yodsin
- Department of Chemistry, Faculty of Science, Silpakorn University, Nakorn Pathom, Thailand
| | - Thanapat Suebrasri
- Faculty of Medical Science, Nakhonratchasima College, Nakhonratchasima, Thailand
| | - Thanaset Senawong
- Department of Biochemistry, Faculty of Science, Khon Kaen University, Khon Kaen, Thailand
| | - Awat Wisetsai
- Department of Industrial Chemistry, Faculty of Applied Science, King Mongkut's University of Technology North Bangkok, Bangkok, Thailand
| |
Collapse
|
3
|
Singh P, Dhole B, Choudhury J, Tuli A, Pandey D, Velpandian T, Gupta S, Chaturvedi PK. Calotropis procera extract inhibits prostate cancer through regulation of autophagy. J Cell Mol Med 2024; 28:e18050. [PMID: 38400579 PMCID: PMC10941509 DOI: 10.1111/jcmm.18050] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/29/2023] [Revised: 11/04/2023] [Accepted: 11/09/2023] [Indexed: 02/25/2024] Open
Abstract
Current treatment options available for prostate cancer (PCa) patients have many adverse side effects and hence, new alternative therapies need to be explored. Anticancer potential of various phytochemicals derived from Calotropis procera has been studied in many cancers but no study has investigated the effect of leaf extract of C. procera on PCa cells. Hence, we investigated the effect of C. procera leaf extract (CPE) on cellular properties of androgen-independent PC-3 and androgen-sensitive 22Rv1 cells. A hydroalcoholic extract of C. procera was prepared and MTT assay was performed to study the effect of CPE on viability of PCa cells. The effect of CPE on cell division ability, migration capability and reactive oxygen species (ROS) production was studied using colony formation assay, wound-healing assay and 2',7'-dichlorodihydrofluorescein diacetate assay, respectively. Caspase activity assay and LDH assay were performed to study the involvement of apoptosis and necrosis in CPE-mediated cell death. Protein levels of cell cycle, antioxidant, autophagy and apoptosis markers were measured by western blot. The composition of CPE was identified using untargeted LC-MS analysis. Results showed that CPE decreased the viability of both the PCa cells, PC-3 and 22Rv1, in a dose- and time-dependent manner. Also, CPE significantly inhibited the colony-forming ability, migration and endogenous ROS production in both the cell lines. Furthermore, CPE significantly decreased NF-κB protein levels and increased the protein levels of the cell cycle inhibitor p27. A significant increase in expression of autophagy markers was observed in CPE-treated PC-3 cells while autophagy markers were downregulated in 22Rv1 cells after CPE exposure. Hence, it can be concluded that CPE inhibits PCa cell viability possibly by regulating the autophagy pathway and/or altering the ROS levels. Thus, CPE can be explored as a possible alternative therapeutic agent for PCa.
Collapse
Affiliation(s)
- Palak Singh
- Department of Reproductive BiologyAll India Institute of Medical SciencesNew DelhiIndia
| | - Bodhana Dhole
- Department of Reproductive BiologyAll India Institute of Medical SciencesNew DelhiIndia
| | - Jaganmoy Choudhury
- Department of Reproductive BiologyAll India Institute of Medical SciencesNew DelhiIndia
| | - Anannya Tuli
- Department of Ocular PharmacologyDr. Rajendra Prasad Centre for Ophthalmic Sciences, All India Institute of Medical SciencesNew DelhiIndia
| | - Deepak Pandey
- Department of Reproductive BiologyAll India Institute of Medical SciencesNew DelhiIndia
| | - Thirumurthy Velpandian
- Department of Ocular PharmacologyDr. Rajendra Prasad Centre for Ophthalmic Sciences, All India Institute of Medical SciencesNew DelhiIndia
| | - Surabhi Gupta
- Department of Reproductive BiologyAll India Institute of Medical SciencesNew DelhiIndia
| | | |
Collapse
|
4
|
Evans J, Akee RK, Chanana S, McConachie GD, Thornburg CC, Grkovic T, O’Keefe BR. National Cancer Institute (NCI) Program for Natural Product Discovery: Exploring NCI-60 Screening Data of Natural Product Samples with Artificial Neural Networks. ACS OMEGA 2023; 8:9250-9256. [PMID: 36936303 PMCID: PMC10018511 DOI: 10.1021/acsomega.2c07416] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 11/18/2022] [Accepted: 02/17/2023] [Indexed: 06/18/2023]
Abstract
National Cancer Institute (NCI) Program for Natural Product Discovery is a new initiative aimed at creating new technologies for natural product-based drug discovery. Here, we present the development of a neural network-based bioinformatics platform for visualization and analysis of natural product high-throughput screening data using the NCI's 60 human tumor cell anticancer drug screen. We demonstrate how the tool enables visualization of similar patterns of response that can be parsed both chemically and taxonomically, grouping NCI-60 biological profiles in one easy-to-use bioinformatics interface.
Collapse
Affiliation(s)
- Jason
R. Evans
- Natural
Products Branch, Developmental Therapeutic Program, Division of Cancer
Treatment and Diagnosis, National Cancer
Institute, Frederick, Maryland 21702-1201, United States
| | - Rhone K. Akee
- Natural
Products Support Group, Leidos Biomedical
Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland 21702-1201, United
States
| | - Shaurya Chanana
- Natural
Products Branch, Developmental Therapeutic Program, Division of Cancer
Treatment and Diagnosis, National Cancer
Institute, Frederick, Maryland 21702-1201, United States
| | - Grant D. McConachie
- Natural
Products Support Group, Leidos Biomedical
Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland 21702-1201, United
States
| | - Christopher C. Thornburg
- Natural
Products Support Group, Leidos Biomedical
Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland 21702-1201, United
States
| | - Tanja Grkovic
- Natural
Products Branch, Developmental Therapeutic Program, Division of Cancer
Treatment and Diagnosis, National Cancer
Institute, Frederick, Maryland 21702-1201, United States
- Molecular
Targets Laboratory, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21702-1201, United States
| | - Barry R. O’Keefe
- Natural
Products Branch, Developmental Therapeutic Program, Division of Cancer
Treatment and Diagnosis, National Cancer
Institute, Frederick, Maryland 21702-1201, United States
- Molecular
Targets Laboratory, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21702-1201, United States
| |
Collapse
|
5
|
Rajkovic J, Novakovic R, Grujic-Milanovic J, Ydyrys A, Ablaikhanova N, Calina D, Sharifi-Rad J, Al-Omari B. An updated pharmacological insight into calotropin as a potential therapeutic agent in cancer. Front Pharmacol 2023; 14:1160616. [PMID: 37138852 PMCID: PMC10149670 DOI: 10.3389/fphar.2023.1160616] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/07/2023] [Accepted: 04/05/2023] [Indexed: 05/05/2023] Open
Abstract
Calotropin is a pharmacologically active compound isolated from milkweed plants like Calotropis procera, Calotropis gigantea, and Asclepias currasavica that belong to the Asclepiadaceae family. All of these plants are recognised as medical traditional plants used in Asian countries. Calotropin is identified as a highly potent cardenolide that has a similar chemical structure to cardiac glycosides (such as digoxin and digitoxin). During the last few years, cytotoxic and antitumor effects of cardenolides glycosides have been reported more frequently. Among cardenolides, calotropin is identified as the most promising agent. In this updated and comprehensive review, we aimed to analyze and discuss the specific mechanisms and molecular targets of calotropin in cancer treatment to open new perspectives for the adjuvant treatment of different types of cancer. The effects of calotropin on cancer have been extensively studied in preclinical pharmacological studies in vitro using cancer cell lines and in vivo in experimental animal models that have targeted antitumor mechanisms and anticancer signaling pathways. The analyzed information from the specialized literature was obtained from scientific databases until December 2022, mainly from PubMed/MedLine, Google Scholar, Scopus, Web of Science, and Science Direct databases using specific MeSH search terms. The results of our analysis demonstrate that calotropin can be a potential chemotherapeutic/chemopreventive adjunctive agent in cancer pharmacotherapeutic management.
Collapse
Affiliation(s)
- Jovana Rajkovic
- Institute for Pharmacology, Clinical Pharmacology and Toxicology, Faculty of Medicine, University of Belgrade, Belgrade, Serbia
| | - Radmila Novakovic
- Institute for Pharmacology, Clinical Pharmacology and Toxicology, Faculty of Medicine, University of Belgrade, Belgrade, Serbia
| | - Jelica Grujic-Milanovic
- Institute for Medical Research, National Institute of the Republic of Serbia, University of Belgrade, Belgrade, Serbia
| | - Alibek Ydyrys
- Biomedical Research Centre, Al-Farabi Kazakh National University, Almaty, Kazakhstan
| | - Nurzhanat Ablaikhanova
- Department of Biophysics, Biomedicine and Neuroscience, Al-Farabi Kazakh National University, Almaty, Kazakhstan
| | - Daniela Calina
- Department of Clinical Pharmacy, University of Medicine and Pharmacy of Craiova, Craiova, Romania
- *Correspondence: Daniela Calina, ; Javad Sharifi-Rad, ; Basem Al-Omari,
| | - Javad Sharifi-Rad
- Facultad de Medicina, Universidad del Azuay, Cuenca, Ecuador
- *Correspondence: Daniela Calina, ; Javad Sharifi-Rad, ; Basem Al-Omari,
| | - Basem Al-Omari
- Department of Epidemiology and Population Health, College of Medicine and Health Sciences, Khalifa University, Abu Dhabi, United Arab Emirates
- *Correspondence: Daniela Calina, ; Javad Sharifi-Rad, ; Basem Al-Omari,
| |
Collapse
|
6
|
Thilagavathi R, Priyankha S, Kannan M, Prakash M, Selvam C. Compounds from diverse natural origin against triple-negative breast cancer: A comprehensive review. Chem Biol Drug Des 2023; 101:218-243. [PMID: 36323650 DOI: 10.1111/cbdd.14172] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/25/2022] [Revised: 10/25/2022] [Accepted: 10/29/2022] [Indexed: 11/05/2022]
Abstract
Triple-negative breast cancer (TNBC) is caused due to the lack of estrogen receptors (ER), progesterone receptors (PR), and human epidermal growth factor 2 (HER2) expression. Triple-negative breast cancer is the most aggressive heterogeneous disease that is capable of producing different clones and mutations. Tumorigenesis in TNBC is caused due to the mutation or overexpression of tumor suppressor genes. It is also associated with mutations in the BRCA gene which is linked to hereditary breast cancer. In addition, PARP proteins and checkpoint proteins also play a crucial function in causing TNBC. Many cell signaling pathways are dysregulated in TNBC. Even though chemotherapy and immunotherapy are good options for TNBC treatment, the response rates are still low in general. Many phytochemicals that are derived from natural compounds have shown very good inhibitions for TNBC. Natural compounds have the great advantage of being less toxic, having lesser side effects, and being easily available. The secondary metabolites such as alkaloids, terpenoids, steroids, and flavonoids in natural products make them promising inhibitors of TNBC. Their compositions also offer vital insights into inhibitory action, which could lead to new cancer-fighting strategies. This review can help in understanding how naturally occurring substances and medicinal herbs decrease specific tumors and pave the way for the development of novel and extremely efficient antitumor therapies.
Collapse
Affiliation(s)
- Ramasamy Thilagavathi
- Department of Biotechnology, Faculty of Engineering, Karpagam Academy of Higher Education, Coimbatore, India
| | - Sridhar Priyankha
- Department of Chemistry, Faculty of Engineering and Technology, SRM Institute of Science and Technology, Chengalpattu, India
| | - Manivel Kannan
- Faculty of Pharmacy, Karpagam Academy of Higher Education, Coimbatore, India
| | - Muthuramalingam Prakash
- Department of Chemistry, Faculty of Engineering and Technology, SRM Institute of Science and Technology, Chengalpattu, India
| | - Chelliah Selvam
- Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, Texas Southern University, Houston, Texas, USA
| |
Collapse
|
7
|
Rubiano-Buitrago P, Pradhan S, Paetz C, Rowland HM. New Structures, Spectrometric Quantification, and Inhibitory Properties of Cardenolides from Asclepias curassavica Seeds. Molecules 2022; 28:molecules28010105. [PMID: 36615300 PMCID: PMC9822358 DOI: 10.3390/molecules28010105] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/16/2022] [Revised: 12/14/2022] [Accepted: 12/20/2022] [Indexed: 12/25/2022] Open
Abstract
Cardiac glycosides are a large class of secondary metabolites found in plants. In the genus Asclepias, cardenolides in milkweed plants have an established role in plant-herbivore and predator-prey interactions, based on their ability to inhibit the membrane-bound Na+/K+-ATPase enzyme. Milkweed seeds are eaten by specialist lygaeid bugs, which are the most cardenolide-tolerant insects known. These insects likely impose natural selection for the repeated derivatisation of cardenolides. A first step in investigating this hypothesis is to conduct a phytochemical profiling of the cardenolides in the seeds. Here, we report the concentrations of 10 purified cardenolides from the seeds of Asclepias curassavica. We report the structures of new compounds: 3-O-β-allopyranosyl coroglaucigenin (1), 3-[4'-O-β-glucopyranosyl-β-allopyranosyl] coroglaucigenin (2), 3'-O-β-glucopyranosyl-15-β-hydroxycalotropin (3), and 3-O-β-glucopyranosyl-12-β-hydroxyl coroglaucigenin (4), as well as six previously reported cardenolides (5-10). We test the in vitro inhibition of these compounds on the sensitive porcine Na+/K+-ATPase. The least inhibitory compound was also the most abundant in the seeds-4'-O-β-glucopyranosyl frugoside (5). Gofruside (9) was the most inhibitory. We found no direct correlation between the number of glycosides/sugar moieties in a cardenolide and its inhibitory effect. Our results enhance the literature on cardenolide diversity and concentration among tissues eaten by insects and provide an opportunity to uncover potential evolutionary relationships between tissue-specific defense expression and insect adaptations in plant-herbivore interactions.
Collapse
Affiliation(s)
- Paola Rubiano-Buitrago
- Research Group Predators and Toxic Prey, Max Planck Institute for Chemical Ecology, Hans Knöll Straße 8, 07745 Jena, Germany
- Research Group Biosynthesis/NMR, Max Planck Institute for Chemical Ecology, Hans Knöll Straße 8, 07745 Jena, Germany
- Correspondence: (P.R.-B.); (H.M.R.)
| | - Shrikant Pradhan
- Research Group Predators and Toxic Prey, Max Planck Institute for Chemical Ecology, Hans Knöll Straße 8, 07745 Jena, Germany
| | - Christian Paetz
- Research Group Biosynthesis/NMR, Max Planck Institute for Chemical Ecology, Hans Knöll Straße 8, 07745 Jena, Germany
| | - Hannah M. Rowland
- Research Group Predators and Toxic Prey, Max Planck Institute for Chemical Ecology, Hans Knöll Straße 8, 07745 Jena, Germany
- Correspondence: (P.R.-B.); (H.M.R.)
| |
Collapse
|
8
|
Meneses-Sagrero SE, Rascón-Valenzuela LA, García-Ramos JC, Vilegas W, Arvizu-Flores AA, Sotelo-Mundo RR, Robles-Zepeda RE. Calotropin and corotoxigenin 3-O-glucopyranoside from the desert milkweed Asclepias subulata inhibit the Na +/K +-ATPase activity. PeerJ 2022; 10:e13524. [PMID: 35673388 PMCID: PMC9167584 DOI: 10.7717/peerj.13524] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/08/2022] [Accepted: 05/10/2022] [Indexed: 01/17/2023] Open
Abstract
Na+/K+-ATPase is an essential transmembrane enzyme found in all mammalian cells with critical functions for cell ion homeostasis. The inhibition of this enzyme by several cardiotonic steroids (CTS) has been associated with the cytotoxic effect on cancer cell lines of phytochemicals such as ouabain and digitoxin. This study evaluated the inhibitory capacity of cardenolides calotropin and corotoxigenin 3-O-glucopyranoside (C3OG) from Asclepias subulata over the Na+/K+-ATPase activity in vitro and silico. The inhibitory assays showed that calotropin and C3OG decreased the Na+/K+-ATPase activity with IC50 values of 0.27 and 0.87 μM, respectively. Furthermore, the molecules presented an uncompetitive inhibition on Na+/K+-ATPase activity, with Ki values of 0.2 μM to calotropin and 0.5 μM to C3OG. Furthermore, the molecular modeling indicated that calotropin and C3OG might interact with the Thr797 and Gln111 residues, considered essential to the interaction with the Na+/K+-ATPase. Besides, these cardenolides can interact with amino acid residues such as Phe783, Leu125, and Ala323, to establish hydrophobic interactions on the binding site. Considering the results, these provide novel evidence about the mechanism of action of cardenolides from A. subulata, proposing that C3OG is a novel cardenolide that deserves further consideration for in vitro cellular antiproliferative assays and in vivo studies as an anticancer molecule.
Collapse
Affiliation(s)
| | | | - Juan C. García-Ramos
- Escuela de Ciencias de la Salud, Universidad Autónoma de Baja California, Ensenada, Baja California, México
| | - Wagner Vilegas
- Instituto de Biociências, São Paulo State University, Sao Paulo, Brasil
| | | | - Rogerio R. Sotelo-Mundo
- Laboratorio de Estructura Molecular, Centro de Investigación en Alimentación y Desarrollo AC, Hermosillo, Sonora, México
| | | |
Collapse
|
9
|
Robles AJ, Dai W, Haldar S, Ma H, Anderson VM, Overacker RD, Risinger AL, Loesgen S, Houghton PJ, Cichewicz RH, Mooberry SL. Altertoxin II, a Highly Effective and Specific Compound against Ewing Sarcoma. Cancers (Basel) 2021; 13:cancers13246176. [PMID: 34944795 PMCID: PMC8699301 DOI: 10.3390/cancers13246176] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/30/2021] [Revised: 11/29/2021] [Accepted: 12/03/2021] [Indexed: 11/16/2022] Open
Abstract
A screening program designed to identify natural products with selective cytotoxic effects against cell lines representing different types of pediatric solid tumors led to the identification of altertoxin II as a highly potent and selective cytotoxin against Ewing sarcoma cell lines. Altertoxin II, but not the related compounds altertoxin I and alteichin, was highly effective against every Ewing sarcoma cell line tested, with an average 25-fold selectivity for these cells as compared to cells representing other pediatric and adult cancers. Mechanism of action studies revealed that altertoxin II causes DNA double-strand breaks, a rapid DNA damage response, and cell cycle accumulation in the S phase. Our studies also demonstrate that the potent effects of altertoxin II are partially dependent on the progression through the cell cycle, because the G1 arrest initiated by a CDK4/6 inhibitor decreased antiproliferative potency more than 10 times. Importantly, the cell-type-selective DNA-damaging effects of altertoxin II in Ewing sarcoma cells occur independently of its ability to bind directly to DNA. Ultimately, we found that altertoxin II has a dose-dependent in vivo antitumor efficacy against a Ewing sarcoma xenograft, suggesting that it has potential as a therapeutic drug lead and will be useful to identify novel targets for Ewing-sarcoma-specific therapies.
Collapse
Affiliation(s)
- Andrew J. Robles
- Department of Pharmacology, The University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, USA; (A.J.R.); (A.L.R.)
- Mays Cancer Center, The University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, USA;
- Greehey Children’s Cancer Research Institute, The University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, USA
| | - Wentao Dai
- Natural Products Discovery Group, Institute for Natural Products Applications and Research Technologies, and Department of Chemistry & Biochemistry, Stephenson Life Science Research Center, University of Oklahoma, Norman, OK 73019, USA; (W.D.); (S.H.); (H.M.); (V.M.A.)
| | - Saikat Haldar
- Natural Products Discovery Group, Institute for Natural Products Applications and Research Technologies, and Department of Chemistry & Biochemistry, Stephenson Life Science Research Center, University of Oklahoma, Norman, OK 73019, USA; (W.D.); (S.H.); (H.M.); (V.M.A.)
| | - Hongyan Ma
- Natural Products Discovery Group, Institute for Natural Products Applications and Research Technologies, and Department of Chemistry & Biochemistry, Stephenson Life Science Research Center, University of Oklahoma, Norman, OK 73019, USA; (W.D.); (S.H.); (H.M.); (V.M.A.)
| | - Victoria M. Anderson
- Natural Products Discovery Group, Institute for Natural Products Applications and Research Technologies, and Department of Chemistry & Biochemistry, Stephenson Life Science Research Center, University of Oklahoma, Norman, OK 73019, USA; (W.D.); (S.H.); (H.M.); (V.M.A.)
| | - Ross D. Overacker
- Department of Chemistry, Oregon State University, Corvallis, OR 97331, USA; (R.D.O.); (S.L.)
| | - April L. Risinger
- Department of Pharmacology, The University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, USA; (A.J.R.); (A.L.R.)
- Mays Cancer Center, The University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, USA;
| | - Sandra Loesgen
- Department of Chemistry, Oregon State University, Corvallis, OR 97331, USA; (R.D.O.); (S.L.)
- Whitney Laboratory for Marine Bioscience, Department of Chemistry, University of Florida, St. Augustine, FL 32080, USA
| | - Peter J. Houghton
- Mays Cancer Center, The University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, USA;
- Greehey Children’s Cancer Research Institute, The University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, USA
| | - Robert H. Cichewicz
- Natural Products Discovery Group, Institute for Natural Products Applications and Research Technologies, and Department of Chemistry & Biochemistry, Stephenson Life Science Research Center, University of Oklahoma, Norman, OK 73019, USA; (W.D.); (S.H.); (H.M.); (V.M.A.)
- Correspondence: (R.H.C.); (S.L.M.); Tel.: +1-405-325-6969 (R.H.C.); +1-210-567-4788 (S.L.M.); Fax: +1-405-325-6111 (R.H.C.); +1-210-567-4300 (S.L.M.)
| | - Susan L. Mooberry
- Department of Pharmacology, The University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, USA; (A.J.R.); (A.L.R.)
- Mays Cancer Center, The University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, USA;
- Correspondence: (R.H.C.); (S.L.M.); Tel.: +1-405-325-6969 (R.H.C.); +1-210-567-4788 (S.L.M.); Fax: +1-405-325-6111 (R.H.C.); +1-210-567-4300 (S.L.M.)
| |
Collapse
|
10
|
He YL, Yang HY, Huang PZ, Feng WJ, Gao K. Cytotoxic cardenolides from Calotropis gigantea. PHYTOCHEMISTRY 2021; 192:112951. [PMID: 34563976 DOI: 10.1016/j.phytochem.2021.112951] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/20/2021] [Revised: 09/06/2021] [Accepted: 09/10/2021] [Indexed: 06/13/2023]
Abstract
Sixteen cardiac glycosides, including five previously undescribed compounds, were extracted and purified from whole plants of Calotropis gigantea (L.). Spectroscopic data and electronic circular dichroism (ECD) analyses were used to determine their structures. Calogiganin C is the first naturally occurring example of a cardenolide containing a 7-membered lactone in ring A. The cytotoxic activities of these compounds against A172, U251, AGS, PANC-1, HepG2, HCT116 and NCI-H226 cell lines were evaluated. Four of them exhibited the most potent growth inhibitory activity against a panel of human cancer cell lines, including A172, U251, AGS, PANC-1 and HCT116. Notably, uscharidin and calotropin showed pronounced cytotoxicities at low nanomolar concentrations against A172 and U251 cells, and possible cell death mechanism studies manifested that these two compounds induced G2/M cell cycle arrest, which demonstrated promising anticancer potential.
Collapse
Affiliation(s)
- Yi-Lin He
- State Key Laboratory of Applied Organic Chemistry, College of Chemistry and Chemical Engineering, Lanzhou University, Lanzhou, 730000, People's Republic of China; Research Institute, Lanzhou Jiaotong University, Lanzhou, 730070, People's Republic of China
| | - Hong-Ying Yang
- State Key Laboratory of Applied Organic Chemistry, College of Chemistry and Chemical Engineering, Lanzhou University, Lanzhou, 730000, People's Republic of China
| | - Pei-Zhi Huang
- State Key Laboratory of Applied Organic Chemistry, College of Chemistry and Chemical Engineering, Lanzhou University, Lanzhou, 730000, People's Republic of China
| | - Wei-Jiao Feng
- State Key Laboratory of Applied Organic Chemistry, College of Chemistry and Chemical Engineering, Lanzhou University, Lanzhou, 730000, People's Republic of China
| | - Kun Gao
- State Key Laboratory of Applied Organic Chemistry, College of Chemistry and Chemical Engineering, Lanzhou University, Lanzhou, 730000, People's Republic of China.
| |
Collapse
|
11
|
Dai L, Wang L, Tan C, Cai J, Shen H, Zhang T, Zhi S, Yang Z, Hu Y, Zhao X, Li D. Sophoridine Derivatives Induce Apoptosis and Autophagy to Suppress the Growth of Triple-Negative Breast Cancer through Inhibition of mTOR Signaling. ChemMedChem 2021; 17:e202100434. [PMID: 34569159 DOI: 10.1002/cmdc.202100434] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/16/2021] [Revised: 09/19/2021] [Indexed: 12/26/2022]
Abstract
In order to improve the antitumor potency and therapeutic margins of natural product sophoridine, its novel nitrogen mustard carbamate derivatives were designed and synthesized. In screening their in vitro activity, we found all the tested compounds were more potent against the highly aggressive triple-negative breast cancer cell line MDA-MB-231. Cellular functional assays showed that representative compounds could induce G1-phase arrest and trigger apoptosis, evidenced by the alteration of Bax, Bcl-2, caspase-3 and PARP levels. Furthermore, these compounds significantly enhanced the autophagic flux with increased expression of LC3-II and Beclin-1, as well as decreased level of p62, which may attribute to simultaneously inhibition of the phosphorylation of p70S6K, 4E-BP1 and AKT, the key substrates of the mTOR signaling pathway. In vivo, two compounds revealed potent antitumor activity in mice bearing MDA-MB-231. Altogether, our work describes novel leads to yield more potent chemotherapeutics against triple-negative breast cancers, possibly mesenchymal stem-like subtype.
Collapse
Affiliation(s)
- Linlin Dai
- Tianjin Institute of Medical & Pharmaceutical Sciences, Tianjin, 300020, China
| | - Luyao Wang
- Tianjin Institute of Medical & Pharmaceutical Sciences, Tianjin, 300020, China
| | - Cheng Tan
- Tianjin Institute of Medical & Pharmaceutical Sciences, Tianjin, 300020, China
| | - Jun Cai
- Tianjin Institute of Medical & Pharmaceutical Sciences, Tianjin, 300020, China
| | - Hongsheng Shen
- Tianjin Institute of Medical & Pharmaceutical Sciences, Tianjin, 300020, China
| | - Ting Zhang
- Tianjin Institute of Medical & Pharmaceutical Sciences, Tianjin, 300020, China
| | - Shuang Zhi
- Tianjin Institute of Medical & Pharmaceutical Sciences, Tianjin, 300020, China
| | - Zibo Yang
- Tianjin Institute of Medical & Pharmaceutical Sciences, Tianjin, 300020, China
| | - Yunhui Hu
- Tianjin Medical University Cancer Institute & Hospital, Tianjin, 300060, China
| | - Xiumei Zhao
- Tianjin Institute of Medical & Pharmaceutical Sciences, Tianjin, 300020, China
| | - Dongdong Li
- Tianjin Institute of Medical & Pharmaceutical Sciences, Tianjin, 300020, China
| |
Collapse
|
12
|
Winitchaikul T, Sawong S, Surangkul D, Srikummool M, Somran J, Pekthong D, Kamonlakorn K, Nangngam P, Parhira S, Srisawang P. Calotropis gigantea stem bark extract induced apoptosis related to ROS and ATP production in colon cancer cells. PLoS One 2021; 16:e0254392. [PMID: 34343190 PMCID: PMC8330925 DOI: 10.1371/journal.pone.0254392] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/29/2021] [Accepted: 06/28/2021] [Indexed: 02/07/2023] Open
Abstract
Conventional chemotherapeutic agents for colorectal cancer (CRC) cause systemic side effects and eventually become less efficacious owing to the development of drug resistance in cancer cells. Therefore, new therapeutic regimens have focused on the use of natural products. The anticancer activity of several parts of Calotropis gigantea has been reported; however, the effects of its stem bark extract on inhibition of cancer cell proliferation have not yet been examined. In this study, the anticancer activity of C. gigantea stem bark extract, both alone and in combination with 5-fluorouracil (5-FU), was evaluated. A crude ethanolic extract was prepared from dry, powdered C. gigantea barks using 95% ethanol. This was then partitioned to obtain dichloromethane (CGDCM), ethyl acetate, and water fractions. Quantitative analysis of the constituent secondary metabolites and calotropin was performed. These fractions exhibited cytotoxicity in HCT116 and HT-29 cells, with CGDCM showing the highest potency in both the cell lines. A combination of CGDCM and 5-FU significantly enhanced the cytotoxic effect. Moreover, the resistance of normal fibroblast, HFF-1, cells to this combination demonstrated its safety in normal cells. The combination significantly enhanced apoptosis through the mitochondria-dependent pathway. Additionally, the combination reduced adenosine triphosphate production and increased the production of reactive oxygen species, demonstrating the mechanisms involved in the induction of apoptosis. Our results suggest that CGDCM is a promising anti-cancer agent and may enhance apoptosis induction by 5-FU in the treatment of CRC, while minimizing toxicity toward healthy cells.
Collapse
Affiliation(s)
- Thanwarat Winitchaikul
- Faculty of Medical Science, Department of Physiology, Naresuan University, Phitsanulok, Thailand
| | - Suphunwadee Sawong
- Faculty of Medical Science, Department of Physiology, Naresuan University, Phitsanulok, Thailand
| | - Damratsamon Surangkul
- Faculty of Medical Science, Department of Biochemistry, Naresuan University, Phitsanulok, Thailand
| | - Metawee Srikummool
- Faculty of Medical Science, Department of Biochemistry, Naresuan University, Phitsanulok, Thailand
| | - Julintorn Somran
- Faculty of Medicine, Department of Pathology, Naresuan University, Phitsanulok, Thailand
| | - Dumrongsak Pekthong
- Faculty of Pharmaceutical Sciences, Department of Pharmacy Practice, Naresuan University, Phitsanulok, Thailand
| | - Kittiya Kamonlakorn
- Faculty of Pharmaceutical Sciences, Department of Pharmaceutical Chemistry and Pharmacognosy, Naresuan University, Phitsanulok, Thailand
| | - Pranee Nangngam
- Faculty of Science, Department of Biology, Naresuan University, Phitsanulok, Thailand
| | - Supawadee Parhira
- Faculty of Pharmaceutical Sciences, Department of Pharmaceutical Technology, Naresuan University, Phitsanulok, Thailand
- * E-mail: (SP); (PS)
| | - Piyarat Srisawang
- Faculty of Medical Science, Department of Physiology, Naresuan University, Phitsanulok, Thailand
- * E-mail: (SP); (PS)
| |
Collapse
|
13
|
Fermaintt CS, Peramuna T, Cai S, Takahashi-Ruiz L, Essif JN, Grant CV, O’Keefe BR, Mooberry SL, Cichewicz RH, Risinger AL. Yuanhuacine Is a Potent and Selective Inhibitor of the Basal-Like 2 Subtype of Triple Negative Breast Cancer with Immunogenic Potential. Cancers (Basel) 2021; 13:cancers13112834. [PMID: 34200174 PMCID: PMC8201195 DOI: 10.3390/cancers13112834] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/11/2021] [Revised: 06/02/2021] [Accepted: 06/03/2021] [Indexed: 12/28/2022] Open
Abstract
The heterogeneity of triple negative breast cancer (TNBC) has led to efforts to further subtype this disease with the hope of identifying new molecular liabilities and drug targets. Furthermore, the finding that TNBC is the most inherently immunogenic type of breast cancer provides the potential for effective treatment with immune checkpoint inhibitors and immune adjuvants. Thus, we devised a dual screen to identify compounds from natural product extracts with TNBC subtype selectivity that also promote the expression of cytokines associated with antitumor immunity. These efforts led to the identification of yuanhuacine (1) as a potent and highly selective inhibitor of the basal-like 2 (BL2) subtype of TNBC that also promoted an antitumor associated cytokine signature in immune cells. The mechanism of action of yuanhuacine for both phenotypes depends on activation of protein kinase C (PKC), defining a novel target for the treatment of this clinical TNBC subtype. Yuanhuacine showed potent antitumor efficacy in animals bearing BL2 tumors further demonstrating that PKC could function as a potential pharmacological target for the treatment of the BL2 subtype of TNBC.
Collapse
Affiliation(s)
- Charles S. Fermaintt
- Department of Pharmacology, Mays Cancer Center, University of Texas Health Science Center San Antonio, San Antonio, TX 78229, USA; (C.S.F.); (L.T.-R.); (J.N.E.); (C.V.G.); (S.L.M.)
| | - Thilini Peramuna
- Department of Chemistry and Biochemistry and Natural Products Discovery Group, University of Oklahoma, Norman, OK 73019, USA; (T.P.); (S.C.); (R.H.C.)
| | - Shengxin Cai
- Department of Chemistry and Biochemistry and Natural Products Discovery Group, University of Oklahoma, Norman, OK 73019, USA; (T.P.); (S.C.); (R.H.C.)
| | - Leila Takahashi-Ruiz
- Department of Pharmacology, Mays Cancer Center, University of Texas Health Science Center San Antonio, San Antonio, TX 78229, USA; (C.S.F.); (L.T.-R.); (J.N.E.); (C.V.G.); (S.L.M.)
| | - Jacob Nathaniel Essif
- Department of Pharmacology, Mays Cancer Center, University of Texas Health Science Center San Antonio, San Antonio, TX 78229, USA; (C.S.F.); (L.T.-R.); (J.N.E.); (C.V.G.); (S.L.M.)
| | - Corena V. Grant
- Department of Pharmacology, Mays Cancer Center, University of Texas Health Science Center San Antonio, San Antonio, TX 78229, USA; (C.S.F.); (L.T.-R.); (J.N.E.); (C.V.G.); (S.L.M.)
| | - Barry R. O’Keefe
- Natural Products Branch, Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis and Molecular Targets Program, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702, USA;
| | - Susan L. Mooberry
- Department of Pharmacology, Mays Cancer Center, University of Texas Health Science Center San Antonio, San Antonio, TX 78229, USA; (C.S.F.); (L.T.-R.); (J.N.E.); (C.V.G.); (S.L.M.)
| | - Robert H. Cichewicz
- Department of Chemistry and Biochemistry and Natural Products Discovery Group, University of Oklahoma, Norman, OK 73019, USA; (T.P.); (S.C.); (R.H.C.)
| | - April L. Risinger
- Department of Pharmacology, Mays Cancer Center, University of Texas Health Science Center San Antonio, San Antonio, TX 78229, USA; (C.S.F.); (L.T.-R.); (J.N.E.); (C.V.G.); (S.L.M.)
- Correspondence: ; Tel.: +1-210-567-6267
| |
Collapse
|
14
|
Ma H, Liang H, Cai S, O'Keefe BR, Mooberry SL, Cichewicz RH. An Integrated Strategy for the Detection, Dereplication, and Identification of DNA-Binding Biomolecules from Complex Natural Product Mixtures. JOURNAL OF NATURAL PRODUCTS 2021; 84:750-761. [PMID: 33226219 PMCID: PMC9229839 DOI: 10.1021/acs.jnatprod.0c00946] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/28/2023]
Abstract
A fundamental factor in natural product drug discovery programs is the necessity to identify the active component(s) from complex chemical mixtures. Whereas this has traditionally been accomplished using bioassay-guided fractionation, we questioned whether alternative techniques could supplement and, in some cases, even supplant this approach. We speculated that a combination of ligand-fishing methods and modern analytical tools (e.g., LC-MS and online natural product databases) offered a route to enhance natural product drug discovery. Herein, a candidate solution referred to as the lickety-split ligand-affinity-based molecular angling system (LLAMAS) is described. This approach utilizes an ultrafiltration-based LC-PDA-MS/MS-guided DNA-binding assay in combination with the (i) Global Natural Products Social Molecular Networking, (ii) Dictionary of Natural Products, and (iii) SciFinder platforms to identify DNA binders in complex chemical mixtures. LLAMAS was initially vetted in tests using known small-molecule DNA binders and then optimized to a 96-well plate-based format. A set of 332 plant samples used in traditional Chinese medicine was screened for DNA-binding activity with LLAMAS, resulting in the identification of seven DNA-binding molecules, including berberine (12), palmatine (13), coptisine (14), fangchinoline (15), tetrandrine (16), daurisoline (17), and dauricine (18). These results demonstrate that LLAMAS is an effective natural product discovery platform for the efficient identification and dereplication of DNA-binding molecules from complex mixtures.
Collapse
Affiliation(s)
- Hongyan Ma
- Department of Chemistry and Biochemistry, Stephenson Life Sciences Research Center, and Natural Products Discovery Group and Institute for Natural Products Applications and Research Technologies, University of Oklahoma, Norman, Oklahoma 73019, United States
| | - Huiyun Liang
- Department of Pharmacology, University of Texas Health Science Center, San Antonio, Texas 78229, United States
| | - Shengxin Cai
- Department of Chemistry and Biochemistry, Stephenson Life Sciences Research Center, and Natural Products Discovery Group and Institute for Natural Products Applications and Research Technologies, University of Oklahoma, Norman, Oklahoma 73019, United States
| | - Barry R O'Keefe
- Natural Products Branch, Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, and Molecular Targets Program, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21702, United States
| | - Susan L Mooberry
- Department of Pharmacology, University of Texas Health Science Center, San Antonio, Texas 78229, United States
| | - Robert H Cichewicz
- Department of Chemistry and Biochemistry, Stephenson Life Sciences Research Center, and Natural Products Discovery Group and Institute for Natural Products Applications and Research Technologies, University of Oklahoma, Norman, Oklahoma 73019, United States
| |
Collapse
|
15
|
S. Kumar A, Khosravi Z. Pharmacognosy and pharmacology of Calotropis gigantea for discovery of anticancer therapeutics. Pharmacogn Mag 2021. [DOI: 10.4103/pm.pm_166_21] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022] Open
|